MediciNova may receive portion of Genzyme's damages from Novartis Zolgensma patent suit

MEDICINOVA INC

Genzyme filed First Amended Complaint on Feb 23, 2022 in Delaware court adding U.S. Patent No. 9,051,542 against Novartis over Zolgensma.
MediciNova, as successor to Avigen, assigned patents to Genzyme in 2005 and may receive a portion of any damages recovered.
Lawsuit targets unauthorized use of rAAV vectors for gene therapy drug Zolgensma.
No guarantee of payment; contingent on Genzyme's recovery via settlement or judgment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.